Efficacy and tolerability of trandolapril in mild to moderate hypertension--a double blind comparative clinical trial with enalapril in Indian population

Several large scale clinical trials have demonstrated that angiotensin converting enzyme inhibitors offer cardiovascular and renal protection independent of their effects on systolic BP. Trandolapril is a new angiotensin converting enzyme inhibitor approved for the treatment of hypertension. The pot...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of physiology and pharmacology 2006-10, Vol.50 (4), p.421
Main Authors: Shankar, Pinakini K, Vidyasagar, Sudha, Adiga, Sachidananda, Naidu, M U R, Usha Rani, P, Rao, Dayasagar, Bairy, K L, Nair, Sreekumaran, Jayaprakash, B, Shashikiran, U, Mukhyapranaprabhu
Format: Article
Language:English
Subjects:
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Blood Pressure - drug effects
Double-Blind Method
Enalapril - adverse effects
Enalapril - therapeutic use
Heart Rate - drug effects
Humans
Hypertension - drug therapy
India
Indoles - adverse effects
Indoles - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several large scale clinical trials have demonstrated that angiotensin converting enzyme inhibitors offer cardiovascular and renal protection independent of their effects on systolic BP. Trandolapril is a new angiotensin converting enzyme inhibitor approved for the treatment of hypertension. The potential advantages of this drug are long duration of action and better tolerability. The objective of the study was to compare the efficacy and tolerability of trandolapril with that of enalapril in mild to moderate hypertension in Indian population. In this double blind, multicentric, parallel comparative clinical study, 120 patients with mild to moderate hypertension were randomly assigned to receive trandolapril 2 mg or enalapril 5 mg once daily for 8 weeks. The attainment of sitting diastolic blood pressure
ISSN:0019-5499